State Street
KPTI icon

State Street’s Karyopharm Therapeutics KPTI Stock Holding History

State Street’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$450K Buy
80,742
+21,800
+37% +$166K ﹤0.01% 3686
2025
Q4 		$434K Buy
58,942
+12,600
+27% +$77.1K ﹤0.01% 3711
2025
Q3 		$303K Buy
46,342
+13,047
+39% +$70.2K ﹤0.01% 3783
2025
Q2 		$144K Buy
33,295
+3,800
+13% +$18.6K ﹤0.01% 3902
2025
Q1 		$110K Sell
29,495
-6
-0% -$51 ﹤0.01% 3953
2024
Q4 		$299K Buy
29,501
+2,200
+8% +$26.6K ﹤0.01% 3756
2024
Q3 		$340K Sell
27,301
-2,953
-10% -$36.7K ﹤0.01% 3674
2024
Q2 		$394K Sell
30,254
-122,132
-80% -$2.02M ﹤0.01% 3612
2024
Q1 		$3.45M Buy
152,386
+15,468
+11% +$271K ﹤0.01% 3084
2023
Q4 		$1.78M Buy
136,918
+718
+0.5% +$9.68K ﹤0.01% 3350
2023
Q3 		$2.74M Sell
136,200
-11,291
-8% -$253K ﹤0.01% 3193
2023
Q2 		$3.96M Sell
147,491
-530,908
-78% -$22.9M ﹤0.01% 3110
2023
Q1 		$39.6M Buy
678,399
+125,930
+23% +$6.22M ﹤0.01% 1803
2022
Q4 		$28.2M Sell
552,469
-48,220
-8% -$3.34M ﹤0.01% 2005
2022
Q3 		$49.2M Sell
600,689
-90,112
-13% -$6.73M ﹤0.01% 1607
2022
Q2 		$46.7M Sell
690,801
-40,312
-6% -$3.7M ﹤0.01% 1692
2022
Q1 		$80.8M Buy
731,113
+363,534
+99% +$45.3M ﹤0.01% 1436
2021
Q4 		$35.5M Sell
367,579
-167,088
-31% -$16.7M ﹤0.01% 2064
2021
Q3 		$46.7M Buy
534,667
+146,897
+38% +$15.2M ﹤0.01% 1861
2021
Q2 		$60M Buy
387,770
+32,285
+9% +$4.69M ﹤0.01% 1708
2021
Q1 		$56.1M Sell
355,485
-506
-0.1% -$107K ﹤0.01% 1656
2020
Q4 		$82.7M Buy
355,991
+36,726
+12% +$8.51M 0.01% 1293
2020
Q3 		$69.9M Buy
319,265
+12,669
+4% +$3.1M ﹤0.01% 1208
2020
Q2 		$87.1M Buy
306,596
+90,097
+42% +$26.6M 0.01% 1060
2020
Q1 		$62.4M Buy
216,499
+1,275
+0.6% +$352K 0.01% 1105
2019
Q4 		$61.9M Buy
215,224
+5,323
+3% +$1.15M ﹤0.01% 1370
2019
Q3 		$30.3M Buy
209,901
+135,253
+181% +$18.3M ﹤0.01% 1783
2019
Q2 		$6.71M Buy
74,648
+10,403
+16% +$835K ﹤0.01% 2676
2019
Q1 		$5.63M Sell
64,245
-103,980
-62% -$11.5M ﹤0.01% 2692
2018
Q4 		$23.6M Buy
168,225
+38,845
+30% +$6.55M ﹤0.01% 1866
2018
Q3 		$33M Sell
129,380
-26,467
-17% -$7.32M ﹤0.01% 1825
2018
Q2 		$39.7M Buy
155,847
+89,918
+136% +$22.2M ﹤0.01% 1637
2018
Q1 		$13.3M Buy
65,929
+26,610
+68% +$5.31M ﹤0.01% 2327
2017
Q4 		$5.66M Buy
39,319
+2,223
+6% +$357K ﹤0.01% 2731
2017
Q3 		$6.11M Buy
37,096
+2,968
+9% +$425K ﹤0.01% 2693
2017
Q2 		$4.63M Buy
34,128
+3,142
+10% +$465K ﹤0.01% 2775
2017
Q1 		$5.97M Buy
30,986
+3,912
+14% +$628K ﹤0.01% 2617
2016
Q4 		$3.82M Buy
27,074
+1,668
+7% +$226K ﹤0.01% 2831
2016
Q3 		$3.71M Buy
25,406
+648
+3% +$77.9K ﹤0.01% 2729
2016
Q2 		$2.49M Buy
24,758
+695
+3% +$90.3K ﹤0.01% 2940
2016
Q1 		$3.22M Buy
24,063
+1,319
+6% +$146K ﹤0.01% 2783
2015
Q4 		$4.52M Buy
22,744
+2,342
+11% +$507K ﹤0.01% 2586
2015
Q3 		$3.22M Sell
20,402
-61,880
-75% -$16.5M ﹤0.01% 2758
2015
Q2 		$33.6M Buy
82,282
+16,464
+25% +$7.12M ﹤0.01% 1511
2015
Q1 		$30.2M Buy
65,818
+20,908
+47% +$9.01M ﹤0.01% 1545
2014
Q4 		$25.2M Buy
44,910
+7,163
+19% +$4.07M ﹤0.01% 1640
2014
Q3 		$19.8M Buy
37,747
+26,482
+235% +$14.9M ﹤0.01% 1760
2014
Q2 		$7.87M Buy
11,265
+4,017
+55% +$1.87M ﹤0.01% 2347
2014
Q1 		$3.36M Sell
7,248
-40
-0.5% -$20.3K ﹤0.01% 2797
2013
Q4 		$2.51M Buy
+7,288
New +$2.01M ﹤0.01% 2961

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

State Street's KPTI Position: Q1 2026 in Review

State Street increased its Karyopharm Therapeutics (KPTI) stake by 37% in Q1 2026, buying an estimated $166K and bringing the position to 80,742 shares worth $450K. The position accounts for ﹤0.01% of the portfolio, ranked #3686.

State Street first reported a position in KPTI in Q4 2013 and has held it in 50 quarters since. The position peaked at $87.1M in Q2 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • State Street held 80,742 shares of Karyopharm Therapeutics worth $450K as of Q1 2026.
  • State Street bought 21,800 Karyopharm Therapeutics shares in Q1 2026, an estimated $166K.
  • Karyopharm Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3686 holding.
  • State Street first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 50 quarters since.
  • State Street's Karyopharm Therapeutics position peaked at $87.1M in Q2 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.